1. Scrip
  2. >>Focus On Asia
  3. >>Japan

Lupin's CEO on the specialty asset hunt in the US

 
• By Anju Ghangurde

Lupin's CEO Vinita Gupta nonchalantly remarks that the company is "impatient" and would like to step up growth in markets like the US via a buy, as she outlines the firm's M&A game plan.

Lupin's CEO Vinita Gupta nonchalantly remarks that the company is "impatient" and would like to step up growth in markets like the US via a buy, as she outlines the firm's M&A game plan.

In an interview with Scrip a day after Lupin snapped up Brazil's Medquímica Indústria Farmacêutica, Ms Gupta and her brother,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

China Sentences Astellas Employee To 3.5 Years In Prison On Spy Charges

 
• By Lisa Takagi

An employee of Astellas faces three and a half years in prison after sentencing by a court in China on espionage charges.

Activist Investor Vs. Japan Pharma: ASKA Plans Poison Pill As Dalton Pushes For MBO

 
• By Lisa Takagi

While ASKA plans to dilute the holding of largest investor Dalton by issuing new shares, the US investment firm continues to push a management buyout option to the mid-sized Japanese pharma company.

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By Lisa Takagi

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

Beyond AI Hype: Tokyo-1’s Real Answer On How To Innovate Pharma R&D

 
• By Lisa Takagi

Bringing supercomputing power to bear on large-scale calculations for pharma R&D, Tokyo-based Xeureka explains the practical use of AI to empower innovation beyond the hype.

More from Focus On Asia